INDBInternet News Database 2.5 Updated 1 min ago · 297 sources Show or hide images Light or dark

Merck KGaA is dropping a heart drug from its Silence deal after a rival's trial failed

1 source1 article First seen Updated United States Truth score 40

Save Like Comments Compare coverage
Image from Quartz

Summary

Merck KGaA will not pursue an advanced study of zerlasiran, which lowers a cholesterol particle, after Novartis ended a similar drug

Description from Quartz.

Who is covering this

  1. Quartz Leans left Factuality: High US
    Merck KGaA is dropping a heart drug from its Silence deal after a rival's trial failed

    Merck KGaA will not pursue an advanced study of zerlasiran, which lowers a cholesterol particle, after Novartis ended a similar drug

Comments

Comments need JavaScript.